The global HGH report discusses the key ongoing trends like licensing agreement, development of needle free injectors and comparison between generic and biosimilar drug versions. On the industry development front, the current inclination is towards creating innovative therapeutic products with novel properties. Furthermore, the major factors driving the HGH market include rising cancer and CKD/ESRD cases and increasing GNI and healthcare expenditure on worldwide basis. In addition, a few factors posing challenges in front of the HGH industry are the off-label HGH use, associated risks and side effects and the escalating price pressure which, to an extent, are hindering the growth and development of the same.

1. View Report Details
Global Human Growth Hormone Market
----------------------------------------------
2012

2. View Report Details
Executive Summary
Pituitary - the master gland of human body is responsible for controlling crucial hormonal secretion, which, in turn, regulates other key aspects of
the body such as temperature, growth, thyroid functioning, urination, and production of other hormones. It is a pea sized gland situated at the
base of brain and is a major component of human body as it expedites the response towards the surrounding environment and settings.
Any deformity or damage to the pituitary gland can adversely impact the production and activity level of the above mentioned hormones, thereby
affecting the body work process and stunting the outcomes especially in the case of growth hormone. Marred pituitary function leads to either
over or under secretion of the somatropin that is the growth hormone. Its over secretion causes disfiguration in the body parts like hands, face,
feet, etc. whereas, its deficiency impedes the growth of body parts/whole body, thus leading to disease states like dwarfism or gigantism.
It is observed that the growth hormone related problems usually affect children and teenagers, but it is seen to grip adults as well though to a
lesser extent. The major factors which vitiate the pituitary operations thus impairing the GH role include kidney malfunction, tumors/cancer
especially associated with brain. There are some other unknown causes as well which are termed as idiopathic. Earlier, to deal with these
predicaments, growth hormone (GH) used to be extracted from the human cadavers but, as time passed and evolution of
technology/tools/techniques/R&D took place, the extraction of GH also got altered and many novel innovations and discoveries were made in the
respective field.
Nowadays, many leading companies are heavily involved in the R&D process for devising longer acting and sustained release versions of the
somatropin which are produced using the recombinant technology. The competition prevalent in the respective industry is heating up day by day.
The human growth hormone market (HGH) is monopolized by a few players viz. Pfizer, NovoNordisk, Eli Lilly and Roche.
The global HGH report also discusses the key ongoing trends like licensing agreement, development of needle free injectors and comparison
between generic and biosimilar drug versions. On the industry development front, the current inclination is towards creating innovative
therapeutic products with novel properties. Furthermore, the major factors driving the HGH market include rising cancer and CKD/ESRD cases
and increasing GNI and healthcare expenditure on worldwide basis. In addition, a few factors posing challenges in front of the HGH industry are
the off-label HGH use, associated risks and side effects and the escalating price pressure which, to an extent, are hindering the growth and
development of the same.
By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the
industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to
determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor
variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.

3. Growth hormone (GH) is a type of peptide hormone produced by the body, responsible for
stimulating cell reproduction, growth and regeneration amongst humans and animals
Global HGH Market Share (2010)
GHD (Growth Hormone Deficiency), occurs when the GH
production is hampered. Any disruption in GH’s endogenous
production causes adverse impact on the body processes, like
muscle protein production, lipid catabolism, and other
direct/indirect functions performed by the hormonal cascade.
As of 2010, HGH market included NovoNordisk’s Norditropin,
which constituted for around …….% of the global market
share, Pfizer’s Genotropin with approximately ……%, followed
by Roche’s Nutropin, and Eli Lilly’s Humatrope with ………%
and ……..% shares, respectively.
The global market for human growth hormone reached
approximately US$.........billion based on key drug sales in
2010. Within the defined period of 6 years, this market
registered a CAGR of ………% from US$...........billion in 2004
to reach US$........billion in 2010.
Global Human Growth Hormone Market (2004-2010)
According to IMS Health, in the US, the total sales of Saizen
for 2010 and 2011 were approximately US$..... million and
US$……….million, respectively.
Another rHGH available in the market is manufactured by
Pfizer, which it markets as Genotropin. The US sales of
Genotropin for 2010 and 2011 were US$........million and
US$...........million, respectively.

4. HGH is a protein hormone, naturally occurring, and is synthesized by the pituitary gland, responsible for
normal human growth and development especially among the teenagers and children
Global hGH-CTP Market Opportunity (2014E-2020E)
With the advent of novel technology in the field of medical
sciences, it is now possible to develop rHGH in wet-labs by
precisely combining the 191 amino acids which compose the
peptide chain of the HGH.
The global opportunity for Prolor’s hGH-CTP is projected to
be US$......million for the year 2014, which is estimated to be
worth US$.........million by 2020, rising at an impressive CAGR
of ……….%.
The GH market share in volume terms has been continuously
Growth Hormone Volume Market share ………. in case of Pfizer, Eli Lilly and Roche thereby
registering a modest …….. in all the cases over a ………. year
(February 2007-February 2012) period.
•Key Trends in the hGH market include:
-Strategic Agreements
-Inclination towards Needle-Free Injectors
-Generic Vs Biosimilar Version of the drugs
On the Industry development front, a lot many improved and
long acting GH products are being developed and are
undergoing clinical trials.

5. Disorders associated with GH depict the underlying lesions of pituitary, hypothalamus or in
the target cells
Global HGH Market Forecast (2009-2015E)
The global HGH market is forecasted to be US$.......billion in 2012 as compared to US$.......... billion estimated for the year 2011, registering a
modest increase of roughly ………%. The same is expected to record a CAGR of about …….% for the period spanning 2010 to 2014 on the back
of rising global cancer cases, global ESRD cases and GNI.
The market for GH products is most evolved in the regions like Europe, the US and Japan wherein the GH products for use among infants
constitute approximately …………% of the total GH demand.
The challenges encountered by the industry include unapproved off-label uses of HGH, possible side effects and other associated risks and
escalating price pressure.
Note: Market attractiveness is inverse of penetration. Low penetration means high attractiveness and vice-versa

6. Table of Contents
Tables and Charts
1. Human Growth Hormone
List of Charts
1.1 Physiological Effects of Growth Hormone
1.2 GH Secretion Control GH’s Physiological Effect
1.3 GH Deficiency (GHD)
GH Secretion Control
Global HGH Market Share (2010)
1.3.1 Disease States Global Human Growth Hormone Market (2004-2010)
Global hGH-CTP Market Opportunity (2014E-2020E)
1.4 Therapeutic and Other Uses of GH/HGH Market Share of Chemical Drugs and Biologics as per Drug Versions
1.5 Recombinant Human Growth Hormone (rHGH)
Number of Cancer Cases Worldwide (2007-2011)
Worldwide Patients with End Stage Renal Disease (2005-2011)
2. Global HGH Market Size Global Healthcare Spending (2005-2015E)
World Gross National Income (2005-2010)
Market Value Growth Hormone Volume Market share (February 2007-February
Market Share
2012)
Roche’s Revenues by Business Segments (2011)
2.1 HGH-CTP Market Opportunity Model Roche’s Revenues and Net Income, 2007-2011
2.2 SRhGH Market Opportunity Model Novo Nordisk Revenue Share by Business Segments (2011)
Novo Nordisk Revenues & Net Income (2008-2011)
3. Market Dynamics
Pfizer’s Revenue Share by Business Segments (2011)
Pfizer’s Revenues & Net Income (2008-2011)
3.1 Key Trends Eli Lilly’s Revenues by Segment (2011)
Eli Lilly’s Revenue and Net Income (2008-2011)
3.1.1 Strategic Agreements Global HGH Market Forecast (2009-2014E)
3.1.2 Inclination towards Needle-Free Injectors
3.1.3 Generic Vs Biosimilar Version of the drugs
3.2 Industry Developments
3.2.1 New Products under Development
3.3 Growth Drivers
3.3.1 Increasing Prevalence of Cancer
3.3.2 Increasing Cases Chronic Kidney Disease (CKD)
3.3.3 Rising Healthcare Expenditure
3.3.4 Increasing Global GNI (Gross National Income)

7. 3.4 Challenges
Tables and Charts
3.4.1 Unapproved/off-label Uses of HGH List of Tables
3.4.2 Possible Side Effects and other Associated Risks
3.4.3 Escalating Price Pressure Worldwide Revenues of Marketed hGH Products (2011)
hGH-CTP US Market Opportunity Model (2014E-2020E)
4. Competitive Landscape hGH-CTP European Market Opportunity Model (2014E-2020E)
SRhGH Market Opportunity Model (2013E-2020E)
Competitive Overview Annual US Sales of rHGH and Injectors
Market Share LG Life Sciences Product under Development
Sustained-release HGH under Development Worldwide
5. Company Profiles Prolor’s Product under Development
GH Products Devised by NovoNordisk
5.1 Roche Holdings AG Growth Hormone Volume Market share (February 2007-February
2012)
Business Overview Dependent & Independent Variables (2006-2011)
Financial Overview Correlation Matrix
Business Strategies Model Summary – Coefficient of Determination
Focus On Innovative Pharmaceuticals Regression Coefficients Output
Leverage Expertise in Molecular Biology
5.2 Novo Nordisk
Business Overview
Financial Overview
Business Strategies
Focus on Hormone Therapy
Leadership in Hemophilia Treatment
5.3 Pfizer, Inc.
Business Overview
Financial Overview
Business Strategies
Focus on Growth
Strategic Acquisitions

8. 5.4 Eli Lilly and Company
Business Overview
Financial Overview
Business Strategies
Focus on Novel Therapeutic Molecules
Capacity Expansion
6. Market Outlook
6.1 Market Forecast
6.2 Forecast Methodology
6.2.1 Dependent and Independent Variables
6.2.2 Correlation Analysis
6.2.3 Regression Analysis

9. Contact Us:
View Report Details
These are abridged and sanitized sample pages from the comprehensive report on the “Global Human Growth Hormone
Market”. To know more about this report or for any customized research requirement, please contact the following:
Koncept Analytics
CS-36, Second Floor, Ansal Plaza
Vaishali, Ghaziabad,
U.P. – 201010
Vikas Gupta T. +91-120-4130959
BD Manager C: +91-9811715635
vikas@konceptanalytics.com
www.konceptanalytics.com